NCT07694817|Not Yet Recruiting
Clinical Predictors of Visual Outcome in Patients Affected With Ocular Surface Diseases
OSD
Loading search results
OSD
Sponsor study identifier
observational
1,000
1 country
1
Study Start
July 2026
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Primary Completion
December 2029
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Study Completion
December 2029
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
This retrospective-prospective study aims to identify the diagnostic parameters most predictive of BSCVA in patients with OSD. Clinical, structural, and biochemical data will be collected from standard-of-care examinations and patient-reported outcome questionnaires. The goal is to determine the most informative biomarkers for visual prognosis, streamline diagnostic workflows, and support individualized management of OSD.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
December 2029
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Click on a node to explore related trials.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
June 23, 2026
Actual (reported)July 2026
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
July 10, 2026
Actual (reported)December 2029
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
December 2029
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Best spectacle-corrected visual acuity (BSCVA) measured in logMAR
Best spectacle-corrected visual acuity will be measured using a standardized Early Treatment Diabetic Retinopathy Study chart at 4 meters after manifest refraction and best spectacle correction. Visual acuity will be reported as logarithm of the minimum angle of resolution. Expected range: -0.3 to 2.0 logMAR. Higher logMAR values indicate worse visual acuity.
Baseline, 6, and 12 months
Maximum keratometry (K max) measured by corneal tomography
Baseline, 6, and 12 months
Central corneal thickness (CCT) measured by corneal tomography
Baseline, 6, and 12 months
The study will enroll adult patients (≥18 years old) of both sexes, representative of the population affected by OSD. No restrictions will be applied regarding ethnicity or socioeconomic background
IRCCS San Raffaele Scientific Institute
Milan, 20132, Italy
First Submitted
June 23, 2026
First Posted
July 10, 2026
Study Start
July 2026
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Primary Completion
December 2029
Corneal nerve density measured by in vivo confocal microscopy
Baseline, 6, and 12 months
Corneal sensitivity measured by Cochet-Bonnet esthesiometer
Baseline, 6, and 12 months
Tear fluid interleukin-1 beta (IL-1β) concentration
Baseline, 6, and 12 months
Contact the study team to confirm eligibility.
Planned date reported by the registry; this milestone is not confirmed as achieved.
Study Completion
December 2029
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Last Updated
July 14, 2026
Record last verified: 2026-07
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: